-+ 0.00%
-+ 0.00%
-+ 0.00%

Alphatec And Theradaptive Announce Strategic Partnership Granting ATEC Exclusive U.S. Rights To OsteoAdapt Bone Graft As Theradaptive Launches Series B To Expand Protein‑Engineering Platform

Benzinga·01/12/2026 14:32:46
Listen to the news

ATEC Secures Exclusive U.S. Rights to OsteoAdapt® Platform in Major Strategic Alignment

Theradaptive Initiates Series B to Advance Proprietary Protein-Engineering Technology

CARLSBAD, Calif. and FREDERICK, Md., Jan. 12, 2026 /PRNewswire/ -- Alphatec Holdings, Inc. (NASDAQ:ATEC), a provider of innovative solutions dedicated to revolutionizing spine surgery, and Theradaptive, Inc., a clinical-stage regenerative medicine company pioneering engineered protein therapeutics, today announced a definitive strategic partnership agreement. Concurrently, Theradaptive announced the initiation of a Series B investment round designed to accelerate the expansion of its proprietary protein-engineering platform across global therapeutic applications.

Under the terms of the agreement, ATEC gains exclusive U.S. commercial rights to market and distribute Theradaptive's OsteoAdapt® osteoinductive bone graft for spinal fusion. This represents a landmark regenerative medicine partnership for the spine industry, structured to deliver significant long-term value through a combination of upfront and milestone payments and a perpetual royalty structure.